Future studies could explore the integration of multi-omics data—such as genomic (e.g., TP53 or CTNNB1 mutations), transcriptomic (e.g., immune signatures, EMT profiles), or radiomic features—which may not only enhance prognostic accuracy but also contribute to a more comprehensive mechanistic understanding of tumor heterogeneity, immune evasion, and the aggressive behavior of LHCC. Here, TP53 is linked to neoplasm.